Herceptin
Active substance: Trastuzumab
Manufacturer: Genentech (USA) / Roche (Worldwide)
Extract from the prescribing information:
"Herceptin can result in sub-clinical and clinical cardiac failure manifesting as CHF and decreased LVEF."
"Herceptin administration can result in serious infusion reactions and pulmonary toxicity. Fatal infusion reactions have been reported."
The above has been extracted from the Herceptin prescribing information on the Genentech webpages.